Low Non-structured Antiretroviral Therapy Interruptions in HIV-Infected Persons Who Inject Drugs Receiving Multidisciplinary Comprehensive HIV Care at an Outpatient Drug Abuse Treatment Center

Vallecillo, Gabriel; Mojal, Sergi; Roquer, Albert; Samos, Pilar; Luque, S.; Martínez, Diana; Martires, Paula K; Torrens, Marta

doi:10.1007/s10461-015-1211-y

Cited by 6 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The center is a cost-free municipal/community-oriented facility located in Barcelona (Spain). 21 Participants signed an informed consent form prior to admission to the program. The characteristics of the methadone therapy provided were no upper limit on methadone dosages prescribed and no restriction on duration of treatment.…”

Section: Methodsmentioning

confidence: 99%

Metabolic Syndrome among Individuals with Heroin use Disorders on Methadone Therapy: Prevalence, Characteristics, and Related Factors

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Metabolic Syndrome among Individuals with Heroin use Disorders on Methadone Therapy: Prevalence, Characteristics, and Related Factors

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…‘Reasons for Previous TI’ was coded as (i) no previous TI, (ii) previous TI due to AE and (iii) previous TI due to other reasons (Figure ) and ‘Previous TI Duration’ variable was coded as (i) 0–14 days, (ii) 15–30 days, (iii) 31–180 days, (iv) 181–365 days and (vi) >365 days. We used these categories to approximately aggregate the TI duration according to the period commonly not considered as a TI: 0–14 days ; and according to those reported in previous literature: 15–30 days , 31–180 days , 181–365 days and >365 days . It was decided a priori that self‐reported adherence levels would not be included in the analyses due to the potential collinearity between adherence and the Reasons for TI variable and that prospective adherence data were only collected in TAHOD from 2011 onwards.…”

Section: Methodsmentioning

confidence: 99%

Effects of unplanned treatment interruptions on HIV treatment failure – results from TAHOD

Jiamsakul¹,

Kerr²,

et al. 2016

Tropical Med Int Health

View full text Add to dashboard Cite

Objectives Treatment interruptions (TI) of combination antiretroviral therapy (cART) are known to lead to unfavourable treatment outcomes but do still occur in resource-limited settings. We investigated the effects of TI associated with adverse events (AEs) and non-AE-related reasons, including their durations, on treatment failure after cART resumption in HIV-infected individuals in Asia. Methods Patients initiating cART between 2006-2013 were included. TI was defined as stopping cART for >1 day. Treatment failure was defined as confirmed virological, immunological or clinical failure. Time to treatment failure during cART was analysed using Cox regression, not including periods off treatment. Co-variables with p<0.10 in univariable analyses were included in multivariable analyses, where p<0.05 was considered statistically significant. Results Of 4549 patients from 13 countries in Asia, 3176 (69.8%) were male and the median age was 34 years. A total of 111 (2.4%) had TIs due to AEs and 135 (3.0%) had TIs for other reasons. Median interruption times were 22 days for AE and 148 days for non-AE TIs. In multivariable analyses, interruptions >30 days were associated with failure (31-180 days HR=2.66, 95%CI (1.70-4.16); 181-365 days HR=6.22, 95%CI (3.26-11.86); and >365 days HR=9.10, 95% CI (4.27-19.38), all p<0.001, compared to 0-14 days). Reasons for previous TI were not statistically significant (p=0.158). Conclusions Duration of interruptions of more than 30 days was the key factor associated with large increases in subsequent risk of treatment failure. If TI is unavoidable, its duration should be minimised to reduce the risk of failure after treatment resumption.

show abstract

“…The centres are part of the public health system and provide integrated patient care to patients, including medical and psychosocial support, through a multidisciplinary team composed of a psychiatrist, a psychologist, an addiction physician, a social worker and addiction nurses. More details on the functioning of CAS have been published elsewhere [ 21 ].…”

Section: Methodsmentioning

confidence: 99%

COVID‐19 vaccination coverage and vaccine hesitancy among people with opioid use disorder in Barcelona, Spain

Vallecillo

Durán

Canosa

et al. 2022

Drug and Alcohol Review

Self Cite

View full text Add to dashboard Cite

Introduction People with substance use disorders are considered a priority group for SARS‐CoV‐2 vaccination as they are at elevated risk of COVID‐19 and its severe complications. However, data are scarce about vaccination coverage in a real‐world setting. Methods A descriptive study was conducted in people with opioid use disorder (OUD) from three public centres for outpatient drug addiction treatment in Barcelona, Spain, who received brief medical advice and were referred to vaccination clinic sites. Results Three hundred and sixty‐two individuals were included: 277 (77%) were men with a mean age of 48.1 ± 8.9 years and 77% were Spanish. Most (90%) participants engaged in polysubstance use and all individuals were on opioid agonist therapy. Psychiatric comorbidity was present in 56% subjects and 32% individuals had ≥1 chronic disease, 30% had HIV and 13% hepatitis C. There were 258 fully vaccinated individuals (71%; 95% confidence interval [CI] 67, 76). Age (odds ratio [OR] 1.04; 95% CI 1.01, 1.08; P < 0.01) and Charlson Comorbidity Index (OR 1.67; 95% CI 1.11, 2.5; P < 0.01) were associated with full vaccination. The vaccination hesitancy causes cited were complacency (53, 51%), convenience (40, 39%) and confidence (11, 10%). Discussion and Conclusions More than two‐thirds of our sample of people with OUD were fully vaccinated. Complacency and convenience represented a significant barrier to complete vaccination among people with OUD on opioid agonist therapy referred to vaccination clinic sites. Additional measures are necessary to increase vaccination, especially for younger individuals and those with less medical comorbidity. Integrating vaccination services in drug outpatient centres could be a useful alternative.

show abstract

Low Non-structured Antiretroviral Therapy Interruptions in HIV-Infected Persons Who Inject Drugs Receiving Multidisciplinary Comprehensive HIV Care at an Outpatient Drug Abuse Treatment Center

Cited by 6 publications

References 36 publications

Metabolic Syndrome among Individuals with Heroin use Disorders on Methadone Therapy: Prevalence, Characteristics, and Related Factors

Metabolic Syndrome among Individuals with Heroin use Disorders on Methadone Therapy: Prevalence, Characteristics, and Related Factors

Effects of unplanned treatment interruptions on HIV treatment failure – results from TAHOD

COVID‐19 vaccination coverage and vaccine hesitancy among people with opioid use disorder in Barcelona, Spain

Contact Info

Product

Resources

About